China’s drug regulator clears wave of home-grown innovative medicines amid biotech boom
China's National Medical Products Administration (NMPA) has approved a significant number of domestically developed innovative medicines, with 15 out of 19 cleared this year originating from Chinese companies. This surge in approvals is part of a broader biotech boom in the country, supported by increased R&D investment and a streamlined regulatory process. Chinese biotech firms have also seen a record increase in cross-border licensing deals, attracting multinational corporations to their early-stage drug pipelines. AI
IMPACT This development signals increased global competition in pharmaceutical R&D and potential for new treatments emerging from China's biotech sector.